New understanding of the genomic diversity of ovarian cancer is already having an effect on drug development in the space, with a possible revival of AstraZeneca LP’s PARP inhibitor olaparib. The company confirms it is looking to tease out the effect of olaparib in a subset of ovarian cancer patients based on BRCA mutations, despite a previous announcement to terminate development in this indication.
Ovarian cancer is a relatively uncommon disease, with 22,000 new cases every year in the U.S., and some experts now...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?